3rd June 2020
Final guidance on use of migraine treatment fremanezumab published
Important step towards availability of fremanezumab in NHS in England and Wales
The National Institute for Health and Care Excellence (NICE) has published its final guidance on fremanezumab (Ajovy). The guidance sets out how the drug can be prescribed in the NHS in England and Wales.
It is an important step towards the availability of it to treat chronic migraine following its approval by NICE in March. Clinical Commissioning Groups in England will now have three months to comply with this recommendation. The NHS in Wales has two months to comply.
Chronic migraine is when a person experiences fifteen or more headache days per month, including having a migraine on eight or more of those days.
Manufactured by Teva Pharmaceuticals, it is one of a new generation of calcitonin gene-related peptide (CGRP) drugs specifically designed to prevent migraine. Migraine preventives are medicines usually taken daily to prevent or reduce the number and severity of migraine attacks. Current preventive options include drugs that have been developed for other conditions and then repurposed for migraine, such as beta blockers or anti-depressants.
NICE has said that the drug should be available for patients living with chronic migraine who have already failed to respond to at least three other migraine preventive drugs.
Patients who think they may be eligible and would benefit from this drug should speak to their NHS clinician about accessing it.
You can read the full guidance on the NICE website.